COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Frontier Registry II Bifurcation Stent System Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00286195
Recruitment Status : Withdrawn (Study was withdrawn due to a business decision.)
First Posted : February 3, 2006
Last Update Posted : May 13, 2015
Information provided by:
Abbott Medical Devices

Brief Summary:
To assess the procedural success, performance, 30-day and 6 month clinical outcome of bifurcation stenting, and the six month incidence of clinically indicated target lesion revascularization with the use of the Abbott Vascular MULTI-LINK FRONTIER Coronary Bifurcation Stent System in patients with de novo or restenotic bifurcation lesions.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Device: Multi-Link Frontier Coronary Stent System Phase 4

Detailed Description:
The purpose of this study is to assess the performance of the Abbott Vascular MULTI-LINK FRONTIER Coronary Bifurcation Stent System (CBSS) with one and six months clinical outcomes, when used for bifurcation de novo or restenotic lesion treatment. The device allows for a stent to be implanted in the main branch and simultaneous preservation and access of the side branch for balloon dilatation or stenting when indicated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Abbott Vascular MULTI -LINK FRONTIER Coronary Bifurcation Stent System Registry II
Study Start Date : December 2004
Actual Primary Completion Date : December 2006
Study Completion Date : December 2006

Arm Intervention/treatment
No Intervention: I
Consecutive patients, open label
Device: Multi-Link Frontier Coronary Stent System
Bare metal stent

Primary Outcome Measures :
  1. Incidence of Major Adverse Cardiac Events (MACE): Death, Q-wave and non-Q wave Myocardial Infarction, Target Lesion Revascularization (main branch and side branch) including PTCA and CABG at 6 months (180 days). [ Time Frame: 180 days and one year ]
  2. Acute ischemic, hemorrhagic and vascular complications. [ Time Frame: one year ]
  3. Target Vessel Failure (TVF) rate (Death, Q-wave and non-Q-wave Myocardial Infarction and Target Vessel Revascularization (TVR) including PTCA and CABG at one month (30 days) and six months (180 days) follow up. [ Time Frame: 6 months ]
  4. Acute success of stent delivery, deployment, and post dilatation. [ Time Frame: 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Other lesions in different epicardial vessels must be successfully treated prior to bifurcation procedure.
  • Native parent vessel suitable to receive at least a 2.5mm x 18mm FRONTIER stent (>2.5mm and <4.0mm diameter with a side branch of >2.0mm) with a lesion length <15mm determined by visual assessment .
  • Target main branch vessel must be a major epicardial native vessel.
  • Appropriate lesion morphology.
  • Target lesion is restenosis following original treatment by PTCA only (no in-stent restenosis).

Exclusion Criteria:

  • Estimated artery reference diameter <2.5mm
  • Patients with diffuse disease defined as long segments of abnormal vessel without interposed areas of normal vessel
  • Target lesion contains thrombus.
  • Target lesion is aorto-ostial or left main stem location.
  • Untreated lesion >50% diameter stenosis proximal or distal to target lesion after the planned target lesion intervention.
  • Patients with a contraindication for anti-platelet / anti-coagulation therapy.
  • Target lesion distal to previously placed stents.
  • Fibrotic or calcified lesions that cannot be pre-dilated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00286195

Sponsors and Collaborators
Abbott Medical Devices
Layout table for investigator information
Principal Investigator: D Dudek, MD Jagiellonian University
Layout table for additonal information
Responsible Party: Matt Kiely, Manager, Medical Information, Abbott Vascular Identifier: NCT00286195    
Other Study ID Numbers: Frontier Registry II
First Posted: February 3, 2006    Key Record Dates
Last Update Posted: May 13, 2015
Last Verified: May 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases